amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Insmed Incorporated's portfolio.
pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension
Insmed Incorporated
Insmed Limited
Insmed Incorporated drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater Township, USA
- Employees
- 1,666
- Programs
- 7
- Drugs
- 18
- Patents
- 0
Insmed Incorporated pipeline
Portfolio lens on 18 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Insmed Incorporated drug portfolio — 18 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amikacin sulfate
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
brensocatib
Respiratory system (R03)US regulatory status: approved. Molecular target: Dipeptidyl peptidase 1.
- Target
- Dipeptidyl peptidase 1
- Mechanism
- Dipeptidyl peptidase I inhibitor
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
Development asset linked to Insmed Incorporated in public FDA and regional records.
-
treprostinil
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Prostacyclin receptor.
- Target
- Prostacyclin receptor
- Mechanism
- Prostanoid IP receptor agonist